收藏切换
Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer
收藏切换
Huili HE1, Haiwei ZHANG2, Dongdong YUAN3, Mengxing LIU4, *
World Clinical Drug | 2023, 44(5) : 506 - 512
Less
收藏切换
World Clinical Drug | 2023, 44(5): 506-512
• Article •
Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer
Full
Huili HE1, Haiwei ZHANG2, Dongdong YUAN3, Mengxing LIU4, *
Affiliations
  • 1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
  • 2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China
  • 3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
  • 4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
Published: 2023-05-10 doi: 10.13683/j.wph.2023.05.017
Outline
收藏切换
Objective

To evaluate the efficacy of osimertinib mesylate in the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) by Meta analysis.

Methods

The literature of randomized controlled trial (RCT) of osimertinib mesylate in the treatment of EGFR mutant NSCLC published in the well-known domestic and foreign databases from the establishment of the database to May 2022 were included, and RevMan5.2 software was used to perform meta-analysis on its effect.

Results

A total of 7 articles were included, including 2 reports in Chinese and 5 reports in English, with a total of 2 591 patients. There were 1 385 cases in the experiment group treated with osimertinib mesylate and 1 206 cases in the control group treated with chemotherapy or gefitinib or erlotinib. The quality of the included articles was up to the standard. The literature on clinical benefit rate and total effective rate was heterogeneous (I2=62%, P=0.02; I2=65%, P=0.04). Random effects model analysis showed no significant difference (RR=0.08, 95%CI: -0.12 -0.14, P=0.159; RR=0.04, 95%CI: -0.02 - 0.11, P=0.136). There were no heterogeneity in progression free survival (PSF), overall survival (OS), survival, and median duration of remission (mDOR, I2=41%, P=0.26; I2=36%, P=0.31; I2=25%, P=0.63; I2=18%, P=0.72). The PSF, OS and mDOR in the experiment group were longer than those in the control group (WMD=4.38, 95%CI: 4.25 - 4.46, P<0.001; WMD=3.97, 95%CI: 3.82 - 4.09, P<0.001; WMD=3.36, 95%CI: 3.14~3.58, P<0.001), and the survival rate of the experiment group was higher than that of the control group (WMD=2.57, 95%CI: 2.25 - 2.7, P<0.001). There was no risk of publication bias.

Conclusion

Compared with chemotherapy or gefitinib or erlotinib, osimertinib mesylate can prolong PSF, OS, mDOR and improve survival rate in patients with EGFR mutant NSCLC.

osimertinib mesylate  /  epidermal growth factor receptor  /  non small cell lung cancer
何慧丽, 张海伟, 袁冬冬, 刘孟兴. 甲磺酸奥希替尼治疗EGFR突变型非小细胞肺癌的效果meta分析. 世界临床药物, 2023 , 44 (5) : 506 -512 . DOI: 10.13683/j.wph.2023.05.017
Huili HE, Haiwei ZHANG, Dongdong YUAN, Mengxing LIU. Meta analysis of efficacy of osimertinib mesylate in the treatment of EGFR mutant non-small cell lung cancer[J]. World Clinical Drug, 2023 , 44 (5) : 506 -512 . DOI: 10.13683/j.wph.2023.05.017
Year 2023 volume 44 Issue 5
8
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.05.017
  • Receive Date:2022-07-26
  • Online Date:2026-11-18
  • Published:2023-05-10
Article Data
Affiliations
History
  • Received:2022-07-26
  • Revised:2022-11-18
Funding
Affiliations
    1.Department of Pharmacy, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
    2.Department of Pharmacy, Hami Central Hospital, Hami 839099, Xinjiang Uygur Autonomous Region, China
    3.Department of oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
    4.Department of Oncology, Anyang Cancer Hospital, Anyang 455001, Henan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.05.017
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT